Eleven children and adolescents with previously normal renal function who received ifosfamide for the treatment of extrarenal solid tumours underwent detailed investigation of glomerular and renal tubular function to assess the incidence and extent of renal damage. None had received cisplatin. Glomerular filtration rate (measured by plasma clearance of 51Cr labelled edetic acid) was reduced in ...

To characterize the excretion of 2-mercaptoethanesulfonate sodium (mesna) administered by intermittent infusion, urinary concentrations of mesna and its corresponding inactive disulfide »eremeasured during 50 courses of ifosfamide (1.6 g/nr for 5 days) and mesna (400 mg/nr at 0.25, 4, and 6 h after each ifosfamide dose) administered i.v. to 19 patients. Some patients had previously received ne...

The present study aim to evaluate the ability of fresh pineapple juice against the genotoxicity side effects of Ifosfamide anti-cancer drug. It was done through using the dominant lethal mutations, one of the short-term tests that adopted in such studies. The results of this study showed that there was a significant reduction of the total and live implants in some weeks and a high morale signif...

Ifosfamide a clinically potent chemotherapeutic agent causes depletion of intracellular glutathione (GSH) levels in different cell types. GSH is the major intracellular reductant against oxidative stress. 4-hydroxyifosfamide (4-OH-IF), the activated form of ifosfamide, depletes GSH levels in T cells and NK cells which is accompanied by a decrease in T cell and NK function. Here we demonstrate f...

BACKGROUND Occupational exposure to hazardous drugs may lead to adverse reproductive effects. There is no safe exposure limit for health care professionals. OBJECTIVES To monitor levels of cyclophosphamide, ifosfamide, and methotrexate contamination in oncology pharmacy and patient care areas in Canadian health care institutions. METHODS The study was conducted in 2014. Hospitals with at le...

The in vivo cytokinetic effects on bone marrow cells from 19 patients with leukemia and lymphoma were inves tigated following a 5-day continuous i.v. infusion of ifosfamide (a congener of cyclophosphamide) at a daily dose of 1.0 to 1.8 g/sq m. There were 8 patients without bone marrow involvement by tumor cells at the time of study, and 11 patients had various degrees of neoplastic re placement...

UNLABELLED Despite a large number of publications on outcomes of second-line chemotherapy for osteosarcoma, there is little consensus on efficacy of the therapy. OBJECTIVE Our objective was to systematically categorize published evidence for chemotherapy for metastatic, relapsed and refractory osteosarcoma in order to provide an updated and comprehensive analysis of the clinical outcomes. M...

Localized activation of the prodrug ifosfamide in or close to tumors by implanting encapsulated ifosfamide-activating cells is an efficacious strategy for tumor therapy. The aim of this study was to evaluate the feasibility of subsieve-size agarose capsules for enclosing the cells in this application. Compared with many conventional microcapsules, subsieve-size agarose capsules are about one-te...

Ifosfamide, a clinically potent chemotherapeutic agent, causes the depletion of intracellular glutathione (GSH) levels in various cell types. GSH is the major intracellular reductant against oxidative stress. 4-Hydroxyifosfamide (4-OH-IF), the activated form of ifosfamide, depletes GSH levels in T cells and natural killer (NK) cells; this is accompanied by a decrease in T-cell and NK-cell funct...